Kyowa Hakko USA

www.kyowa-usa.com

Kyowa Hakko U.S.A., Inc. is the North & South American office for Kyowa Hakko Bio Co., Ltd. As an international health ingredients manufacturer and a world leader in the development, manufacturing and marketing of nutraceuticals, pharmaceuticals and food products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ORI BIOTECH RAISES $30 MILLION $30 MILLION SERIES A FINANCING ROUND TO ADVANCE INNOVATION IN CELL AND GENE THERAPY MANUFACTURING

Ori Biotech | October 15, 2020

news image

Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company's total funding to date to $41 million. The new funding will be used to help bring Ori's innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers. The Series A investor s...

Read More

MedTech, Industrial Impact

BIO-TECHNE AND CST PARTNER TO VALIDATE SIMPLE WESTERN ANTIBODIES

Bio-Techne | February 15, 2023

news image

On February 14, 2023, Bio-Techne Corporation and Cell Signaling Technology (CST) announced that CST antibodies now have Simple Western™ validation. This will make it easier for researchers from numerous disciplines to study essential molecular signaling pathways on a reliable and validated platform. Accurate data must be obtained quickly and efficiently in order to advance drug discovery and development. This continued collaboration will provide a broader menu of Simple We...

Read More

Cell and Gene Therapy

ASTELLAS AND DYNO THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION TO DEVELOP NEXT-GENERATION AAV GENE THERAPY VECTORS FOR SKELETAL AND CARDIAC MUSCLE

Astellas Pharma Inc. and Dyno Therapeutics, Inc. | December 02, 2021

news image

Astellas Pharma Inc. and Dyno Therapeutics, Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform. Dyno's CapsidMap platform represents a transformative approach applying in vivo experimental data and machine learning to create novel AAV capsids – the cell-targeting protein shells of viral vectors...

Read More

RELAY THERAPEUTICS ANNOUNCES FORMATION OF ONCOLOGY ADVISORY BOARD

BioSpace | March 04, 2020

news image

Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, announced today the appointment of top oncology experts, scientists and leaders to its newly formed oncology advisory board. “We are at a pivotal moment in the company’s growth and development as we become a clinical-stage company and we are delighted to have such an esteemed group of leaders to advise and support our team,” said Don Bergstrom, M.D., Ph.D., executive vice pre...

Read More
news image

ORI BIOTECH RAISES $30 MILLION $30 MILLION SERIES A FINANCING ROUND TO ADVANCE INNOVATION IN CELL AND GENE THERAPY MANUFACTURING

Ori Biotech | October 15, 2020

Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company's total funding to date to $41 million. The new funding will be used to help bring Ori's innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers. The Series A investor s...

Read More
news image

MedTech, Industrial Impact

BIO-TECHNE AND CST PARTNER TO VALIDATE SIMPLE WESTERN ANTIBODIES

Bio-Techne | February 15, 2023

On February 14, 2023, Bio-Techne Corporation and Cell Signaling Technology (CST) announced that CST antibodies now have Simple Western™ validation. This will make it easier for researchers from numerous disciplines to study essential molecular signaling pathways on a reliable and validated platform. Accurate data must be obtained quickly and efficiently in order to advance drug discovery and development. This continued collaboration will provide a broader menu of Simple We...

Read More
news image

Cell and Gene Therapy

ASTELLAS AND DYNO THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION TO DEVELOP NEXT-GENERATION AAV GENE THERAPY VECTORS FOR SKELETAL AND CARDIAC MUSCLE

Astellas Pharma Inc. and Dyno Therapeutics, Inc. | December 02, 2021

Astellas Pharma Inc. and Dyno Therapeutics, Inc. announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform. Dyno's CapsidMap platform represents a transformative approach applying in vivo experimental data and machine learning to create novel AAV capsids – the cell-targeting protein shells of viral vectors...

Read More
news image

RELAY THERAPEUTICS ANNOUNCES FORMATION OF ONCOLOGY ADVISORY BOARD

BioSpace | March 04, 2020

Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, announced today the appointment of top oncology experts, scientists and leaders to its newly formed oncology advisory board. “We are at a pivotal moment in the company’s growth and development as we become a clinical-stage company and we are delighted to have such an esteemed group of leaders to advise and support our team,” said Don Bergstrom, M.D., Ph.D., executive vice pre...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us